Диссертация (1154919), страница 19
Текст из файла (страница 19)
// Liver Int. 2010 Feb;30(2):268-74.156. Khoruts A., Stahnke L., McClain C. J., Logan G., Allen J. I. Circulating tumornecrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholicpatients. Hepatology 1991;13:267–276.157. Kinoshita J., Fushida S., Harada S., Makino I., Nakamura K., Oyama K., et al.Type IV collagen levels are elevated in the serum of patients with peritonealdissemination of gastric cancer // Oncology Letters.
2010; 1: 989-994.158. Knauf H., Mutschler E. Liver cirrhosis with ascites: pathogenesis of resistance todiuretics and long-term efficacy and safety of torasemide // Cardiology 1994;84 Suppl2:87–98.159. Lackner C. Comparison and validation of simple noninvasive tests for predictionof fibrosis in chronic hepatitis C / Lackner C., Struber G., Liegl B., Leibl S., Ofner P.,Bankuti C., et al. // Hepatology 2005;41:1376–1382.104160.
Lars Møller Возможно ли употреблять алкоголь без вреда для моего здоровья:вопросы и ответы / интернет ресурс: euro.who.int/ru/health-topics/diseaseprevention/alcohol-use/data-and-statistics/q-and-a-how-can-i-drink-alcohol-safely.161. Lau DT, Kleiner DE, Park Y, Di Bisceglie AM, Hoofnagle JH. Resolution ofchronic delta hepatitis after 12 years of interferon alfa therapy. Gastroenterology 1999;117: 1229–33.162. Ledinghen V. New FibroScan probe for obese patients: A pilot study of feasibilityand performances in patients with BMI >= 30kg/m2 / Ledinghen V., Fournier C., MietteV., et al.
// J Hepatol 2009;50(Suppl 1):S359. (Abst)163. Ledinghen V. Transient elastography (FibroScan) / Ledinghen V., Vergniol J. //Gastroenterol Clin Bio 2008;32:58-67.164. Lefkowitch J.H. Morphology of alcoholic liver disease / Lefkowitch J.H. // ClinLiver Dis 2005; 9: 37–53.165. Leroy V. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C:comparison with PIIINP and hyaluronic acid / Leroy V., Monier F., Bottari S. et al.
//Am. J. Gastroenterol. – 2004. –v. 99. – p. 271–279.166. Li J., Rosman A.S., Leo M.A., Nagai Y., Lieber C.S. Tissue inhibitor ofmetalloproteinase is increased in the serum of precirrhotic and cirrhotic alcoholicpatients and can serve as a marker of fibrosis // Hepatology. 1994; 19: 1418-1423.167. Maillard M., Sorrell M., 2008168. Mandrekar P. An essential role for MCP-1 in alcoholic liver injury: regulation ofpro-inflammatory cytokines and hepatic steatosis / Mandrekar P., Ambade A., Lim A.,Szabo G., Catalano D.
// Hepatology 2011 December ; 54(6): 2185–2197.105169. Marcellin P. Noninvasive assessment of liver biopsy by stiffness measurement inpatient with chronic hepatitis B / Marcellin P., Ziol M., Bedossa P. et al. // Liver Int.2009.-Vol. 29.-P242-247.170. Marelli A., Bodini P., Reggiani A., Quinzani M., Dizioli P., Tonghini L.Comparison between torasemide and furosemide in the treatment of ascites in cirrhoticpatients // Minerva Med 1997;88(3):109–115.171. Masuzaki R., Tateishi R., Yoshida H., Goto E., Sato T., Ohki T., et al. Prospectiverisk assessment for hepatocellular carcinoma development in patients with chronichepatitis C by transient elastography // Hepatology 2009;49:1954–1961.172.
McCla in C.J., Song Z., Barve S.S., Hill D.B., Deaciuc I. Recent advances inalcohol liver disease. VI. Dysregulated cytokine metabolism in alcoholic liver disease //Am. J. Physiol. Gastrointest. Liver Physiol. 2004; 287:497-502.173. McHutchison J.G., Blatt L.M., de Medina M., Craig J.R., Conrad A., Schiff E.R.,Tong M.J. Measurement of serum hyaluronic acid in patients with chronic hepatitis Cand its relationship to liver histology. Consensus Interferon Study Group // J.Gastroenterol. Hepatol.–2000.– v.
15.– p. 945-951.174. Mello T., Ceni E., Surrenti C., Galli A.. Alcohol induced hepatic fibrosis: role ofacetaldehyde. Mol Aspects Med 2008; 29: 17-21.175. Millonig G. Extrahepatic cholestasis increases liver stiffness (FibroScan)irrespective of fibrosis / Millonig G., Reimann F.M., Friedrich S., Fonouni H., MehrabiA., Buchler M.
W., H. Karl Seitz, S. Mueller // Hepatology 2008;48:1718-1723.176. Millonig G. Liver stiffness is directly influenced by central venous pressure /Millonig G., Friedrich S., Adolf S., et al. // J Hepatol 2010;52:206-210.177. Moore К.P., Aithal G.Р. Guidelines on the management of ascites in cirrhosis //Gut 2006, Oct; 55(Suppl 6):1–12.106178. Moshage H., Casini A., Lieber C.S. Acetaldehyde selectively stimulates collagenproduction in cultured rat liver fat-storing cells but not in hepatocytes. Hepatology1990; 12: 511-518179. Myers R.P.
Biochemical markers of liver fibrosis: a comparison with historicalfeatures in patients with chronic hepatitis C / Myers R.P., Ratziu V., Imbert-Bismut F.,Charlotte F., Poynard T.; MULTIVIRC Group. // Am J Gastroenterol. 2002Sep;97(9):2419-2425.180. Mueller S. Non-invasive diagnosis of alcoholic liver disease / Mueller S., SeitzH.K., Rausch V. // World J Gastroenterol. 2014 Oct 28;20(40):14626-14641.181. Nguyen-Khac E.
Assessment of asymptomatic liver fibrosis in alcoholic patientsusing fibroscan: prospective comparison with seven non-invasive laboratory tests /Nguyen-Khac E., Chatelain D., Tramier B., Decrombecque C., Robert B., Joly J.P.,Brevet M., Grignon P., Lion S., Le Page L., Dupas J.L. // Aliment Pharmacol Ther2008; 28: 1188-1198.182.
Ngo Y. FibroTest and ActiTest accurately predict risk of liver decompensation anddeath in patients with chronic hepatitis B / Ngo Y., Benhamou Y., Munteanu M., et al. //Hepatology 2007;46:637A.183. Nøjgaard C. Serum levels of YKL-40 and PIIINP as prognostic markers in patientswith alcoholic liver disease / Nøjgaard C., Johansen J.S., Christensen E., SkovgaardL.T., Price P.A., Becker U. // J. Hepatol.
– 2003. – v. 39. – p. 179-186.184. Niemela O., Juvonen T., Pakkila S. Immunohistochemical demonstration ofacetaldehyde modified epitopes in human liver after alcohol consumption // J. Clin. Invest. 1991; 87: 1367-1374.185. Parés A. Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver diseaseand is useful as a marker of fibrosis / Parés A., Deulofeu R., Giménez A., Caballería L.,107Bruguera M., Caballería J., Ballesta A.M., Rodés J. // Hepatology. – 1996. – v.
24. – p.1399-1403.186. Pavlov C.S. Transient elastography for diagnosis of stages of hepatic fibrosis andcirrhosis in people with alcoholic liver disease / Pavlov C.S., Casazza G., Nikolova D.,Tsochatzis E., Burroughs A.K., Ivashkin V.T., et al. // Cochrane Database Syst Rev2015;1:CD010542.187. Pinzani M. Non-invasive evaluation of hepatic fibrosis: don’t count your chickensbefore they’re hatched / Pinzani M.
// Gut 2006;55:310–312.188. Poynard Т. Biochemical markers of liver fibrosis in patients infected by hepatitis Сvirus: longitudinal validation in a randomized trial / Poynard Т., Imbert-Bismut F.,Ratziu V. et al. // J. Viral. Hep. — 2002. — Vol. 9. — P. 128-133.189. Poynard T. Meta-analyses of Fibrotest diagnostic value in chronic liver disease /Poynard T., Morra R., Halfon P., Castera L., Ratziu V., Imbert Bismut F., et al.
// BMCGastroenterol 2007;7:40.190. Poynard T. Prospective analysis of discordant results between biochemical markersand biopsy in patients with chronic hepatitis C / Poynard T., Munteanu M., ImbertBismut F., Charlotte F., Thabut D., Le Calvez S., et al. // Clin Chem 2004;10:10.191. Poynard T. Appropriateness of liver biopsy / Poynard T., Ratziu V., Bedossa P. // JGastroenterol 2009; 14:543-548.192. Poynard T. A prospective assessment of the inter-laboratory variability ofbiochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients withchronic liver disease // Comp Hep 2008; 2: 3-7.193. Poynard Т.
Natural history of liver fibrosis progression in patients with chronichepatitis C. The OBSVIRC, METAVIR, CLINIVIR and DOSVIRG group / Poynard Т.,Bedossa Р., Opolon P. // Lancet. — 1997. — V. 349. — P. 825-832.108194. Poynard T. Rates and risk factors of liver fibrosis progression in patients withchronic hepatitis C / Poynard T., Ratziu V., Charlotte F., Goodman Z., McHutchison J.,Albrecht J. // J Hepatol. 2001. Vol. 34. P. 730—739.195.
Poynard T. Viral Hepatitis, Third Edition. Chapter 31. Progression of Fibrosis / T.Poynard, V. Ratziu, Y. Benhamou, D. Thabut, J. Moussalli/ Wiley Online Library196. Purohit V., Gao G., Song B.J. Molecularmechanisms of alcoholic fatty liver //Alcohol. Clin. Exp. Res. 2009; 33: 191-205.197. Recklies AD The chitinase 3-like protein human cartilage glycoprotein 39 (HCgp39) stimulates proliferation of human connective-tissue cells and activatesboth extracellular signal-regulated kinase- and protein kinase B-mediated signalingpathways / Recklies AD, White C, Ling H. // Biochem J 2002;365:119–126.198. Rehm J. Global burden of disease and injury and economic cost attributable toalcohol use and alcohol-use disorders / Rehm J., Mathers C., Popova S.,Thavorncharoensap M., Teerawattananon Y., Patra J. // Lancet.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
